spironolactone has been researched along with Hyperandrogenism in 31 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Hyperandrogenism: A condition caused by the excessive secretion of ANDROGENS from the ADRENAL CORTEX; the OVARIES; or the TESTES. The clinical significance in males is negligible. In women, the common manifestations are HIRSUTISM and VIRILISM as seen in patients with POLYCYSTIC OVARY SYNDROME and ADRENOCORTICAL HYPERFUNCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the effects of ethinyl estradiol (EE) 30 mcg/desogestrel 150 mcg plus spironolactone 25 mg/day (group A) versus EE 35 mcg/cyproterone acetate 2 mg (group B) on hyperandrogenism and metabolism in PCOS." | 9.20 | Comparison of desogestrel/ethinyl estradiol plus spironolactone versus cyproterone acetate/ethinyl estradiol in the treatment of polycystic ovary syndrome: a randomized controlled trial. ( Jongwutiwes, T; Leelaphiwat, S; Lertvikool, S; Rattanasiri, S; Sukprasert, M; Tabcharoen, C; Weerakiet, S, 2015) |
| " It also indicates that the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism as compared to metformin alone." | 9.19 | In PCOS patients the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism than metformin alone. ( Belfiore, A; D'Orrico, B; Fava, A; Fruci, B; Guzzi, P; Malaguarnera, R; Mazza, A; Veltri, P, 2014) |
| "Our aim was to conduct a hybrid systematic review of the evidence for benefits and potential harms of oral spironolactone in the management of acne in adult females." | 8.95 | Oral Spironolactone for Acne Vulgaris in Adult Females: A Hybrid Systematic Review. ( Del Rosso, JQ; Eady, EA; Fedorowicz, Z; Layton, AM; van Zuuren, EJ; Whitehouse, H, 2017) |
| "The aim of this study was to compare the efficacy and safety of adding metformin or spironolactone to rosiglitazone in women with polycystic ovary syndrome (PCOS)." | 5.34 | Coadministration of metformin or spironolactone enhances efficacy of rosiglitazone in management of PCOS. ( Bhat, D; Butt, TP; Choh, N; Ganie, MA; Gupta, N; Masoodi, SR; Nisar, S; Rashid, A; Sofi, NY; Sood, M; Wani, IA, 2020) |
| "To compare the effects of ethinyl estradiol (EE) 30 mcg/desogestrel 150 mcg plus spironolactone 25 mg/day (group A) versus EE 35 mcg/cyproterone acetate 2 mg (group B) on hyperandrogenism and metabolism in PCOS." | 5.20 | Comparison of desogestrel/ethinyl estradiol plus spironolactone versus cyproterone acetate/ethinyl estradiol in the treatment of polycystic ovary syndrome: a randomized controlled trial. ( Jongwutiwes, T; Leelaphiwat, S; Lertvikool, S; Rattanasiri, S; Sukprasert, M; Tabcharoen, C; Weerakiet, S, 2015) |
| " It also indicates that the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism as compared to metformin alone." | 5.19 | In PCOS patients the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism than metformin alone. ( Belfiore, A; D'Orrico, B; Fava, A; Fruci, B; Guzzi, P; Malaguarnera, R; Mazza, A; Veltri, P, 2014) |
| "Our aim was to conduct a hybrid systematic review of the evidence for benefits and potential harms of oral spironolactone in the management of acne in adult females." | 4.95 | Oral Spironolactone for Acne Vulgaris in Adult Females: A Hybrid Systematic Review. ( Del Rosso, JQ; Eady, EA; Fedorowicz, Z; Layton, AM; van Zuuren, EJ; Whitehouse, H, 2017) |
| " Patients with clinical hyperandrogenism who received treatment with cyproterone acetate and then spironolactone were included." | 3.96 | [Spironolactone as a relay for cyproterone acetate in hyperandrogenic women]. ( Broux, E; Catteau-Jonard, S; Dewailly, D, 2020) |
| " 51 women completed a 6-month OCP trial (20 µg ethinyl estradiol + 75 µg gestodene, 21/28 days per cycle, plus 100 mg spironolactone in 32 women with moderate to severe hirsutism)." | 3.78 | Aromatase gene polymorphism does not influence clinical phenotype and response to oral contraceptive pills in polycystic ovary syndrome women. ( Maier, PS; Spritzer, PM, 2012) |
| "(i) The term "female pattern hair loss" should be used, avoiding the previous terms of alopecia or androgenetic alopecia." | 2.61 | Female Pattern Hair Loss and Androgen Excess: A Report From the Multidisciplinary Androgen Excess and PCOS Committee. ( Azziz, R; Bergfeld, W; Carmina, E; Escobar-Morreale, HF; Futterweit, W; Huddleston, H; Lobo, R; Olsen, E, 2019) |
| "Hirsutism is the excessive growth of terminal hair in a typical male pattern in a female." | 2.61 | Hirsutism in Women. ( Bain, J; Matheson, E, 2019) |
| "Flutamide was more effective than placebo in two studies (MD -7·60, 95% CI: -10·53 to -4·67 and MD -7·20, 95% CI: -10·15 to -4·25), as was spironolactone (MD -7·69, 95% CI: -10·12 to -5·26)." | 2.53 | Interventions for hirsutism excluding laser and photoepilation therapy alone: abridged Cochrane systematic review including GRADE assessments. ( Fedorowicz, Z; van Zuuren, EJ, 2016) |
| "Acne is an off-label use of some COCs." | 1.72 | Female Pelvic Conditions: Polycystic Ovary Syndrome. ( Brady, PH; Gin, GT; Rosenblum, E; Wilkinson, LD, 2022) |
| "Successful treatment of hirsutism with combination OC+SPL requires at least 6 months of therapy, with the proportion of satisfied patients continuing to increase with treatment duration." | 1.48 | Long-Term Response of Hirsutism and Other Hyperandrogenic Symptoms to Combination Therapy in Polycystic Ovary Syndrome. ( Azziz, R; Ezeh, U; Huang, A; Landay, M, 2018) |
| "Polycystic ovary syndrome is the underlying cause in the vast majority of patients with hirsutism; however, it should be kept in mind that it can only be diagnosed after exclusion of some other diseases such as non-classical congenital adrenal hyperplasia, Cushing's syndrome, hyperprolactinemia and acromegaly." | 1.39 | Hirsutism - from diagnosis to use of antiandrogens. ( Karaca, Z; Kelestimur, F; Unluhizarci, K, 2013) |
| "Insulin resistance was observed in both ovarian and nonovarian hyperandrogenism, as distinguished by acute GnRH agonist testing." | 1.29 | The insulin resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment: evidence that androgens impair insulin action in women. ( Brun, E; Caputo, M; Castello, R; Furlani, L; Magnani, CM; Moghetti, P; Muggeo, M; Negri, C; Tosi, F, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (25.81) | 18.2507 |
| 2000's | 4 (12.90) | 29.6817 |
| 2010's | 14 (45.16) | 24.3611 |
| 2020's | 5 (16.13) | 2.80 |
| Authors | Studies |
|---|---|
| Wilkinson, LD | 1 |
| Brady, PH | 1 |
| Gin, GT | 1 |
| Rosenblum, E | 1 |
| Ganie, MA | 1 |
| Rashid, A | 1 |
| Sood, M | 1 |
| Sofi, NY | 1 |
| Wani, IA | 1 |
| Nisar, S | 1 |
| Butt, TP | 1 |
| Gupta, N | 1 |
| Bhat, D | 1 |
| Choh, N | 1 |
| Masoodi, SR | 1 |
| Zeng, X | 1 |
| Xie, YJ | 1 |
| Liu, YT | 1 |
| Long, SL | 1 |
| Mo, ZC | 1 |
| Broux, E | 1 |
| Dewailly, D | 1 |
| Catteau-Jonard, S | 1 |
| Dhurat, R | 1 |
| Shukla, D | 1 |
| Lim, RK | 1 |
| Wambier, CG | 1 |
| Goren, A | 1 |
| Ezeh, U | 1 |
| Huang, A | 1 |
| Landay, M | 1 |
| Azziz, R | 3 |
| Carmina, E | 2 |
| Bergfeld, W | 1 |
| Escobar-Morreale, HF | 1 |
| Futterweit, W | 1 |
| Huddleston, H | 1 |
| Lobo, R | 1 |
| Olsen, E | 1 |
| Matheson, E | 1 |
| Bain, J | 1 |
| Mazza, A | 1 |
| Fruci, B | 1 |
| Guzzi, P | 1 |
| D'Orrico, B | 1 |
| Malaguarnera, R | 1 |
| Veltri, P | 1 |
| Fava, A | 1 |
| Belfiore, A | 1 |
| Unluhizarci, K | 1 |
| Karaca, Z | 1 |
| Kelestimur, F | 1 |
| Leelaphiwat, S | 1 |
| Jongwutiwes, T | 1 |
| Lertvikool, S | 1 |
| Tabcharoen, C | 1 |
| Sukprasert, M | 1 |
| Rattanasiri, S | 1 |
| Weerakiet, S | 1 |
| Bettoli, V | 1 |
| Zauli, S | 1 |
| Virgili, A | 1 |
| van Zuuren, EJ | 2 |
| Fedorowicz, Z | 2 |
| Sedhom, R | 1 |
| Hu, S | 1 |
| Ohri, A | 1 |
| Infantino, D | 1 |
| Lubitz, S | 1 |
| Layton, AM | 1 |
| Eady, EA | 1 |
| Whitehouse, H | 1 |
| Del Rosso, JQ | 1 |
| Bachelot, A | 1 |
| Chabbert-Buffet, N | 1 |
| Salenave, S | 1 |
| Kerlan, V | 1 |
| Galand-Portier, MB | 1 |
| Artini, PG | 1 |
| Di Berardino, OM | 1 |
| Simi, G | 1 |
| Papini, F | 1 |
| Ruggiero, M | 1 |
| Monteleone, P | 1 |
| Cela, V | 1 |
| Maier, PS | 2 |
| Mattiello, SS | 1 |
| Lages, L | 1 |
| Spritzer, PM | 2 |
| Amesse, LS | 1 |
| Ding, X | 1 |
| Pfaff-Amesse, T | 1 |
| Thiboutot, D | 1 |
| Chen, W | 1 |
| Fleischman, A | 1 |
| Mansfield, J | 1 |
| Vĕtr, M | 1 |
| Sobek, A | 1 |
| Prezelj, J | 2 |
| Kocijancic, A | 2 |
| Moghetti, P | 1 |
| Tosi, F | 1 |
| Castello, R | 1 |
| Magnani, CM | 1 |
| Negri, C | 1 |
| Brun, E | 1 |
| Furlani, L | 1 |
| Caputo, M | 1 |
| Muggeo, M | 1 |
| Koloszár, S | 1 |
| Szöllösi, J | 1 |
| Bártfai, G | 1 |
| Zemtsov, A | 1 |
| Wilson, L | 1 |
| Lobo, RA | 1 |
| Gregoriou, O | 1 |
| Bakas, P | 1 |
| Konidaris, S | 1 |
| Papadias, K | 1 |
| Mathiopoulos, D | 1 |
| Creatsas, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effectiveness of the Combination Liraglutide and Metformin on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With Polycystic Ovarian Syndrome, Obesity and Infertility[NCT05952882] | Phase 3 | 188 participants (Anticipated) | Interventional | 2023-11-01 | Not yet recruiting | ||
| International Phase III, Multi Center, Randomized, Double Blind, Placebo and Active Controlled and Parallel Group Clinical Trial to Evaluate the Efficacy and Safety of Oral Minoxidil 1 mg in Female Patients With Androgenetic Alopecia[NCT05888922] | Phase 3 | 520 participants (Anticipated) | Interventional | 2024-03-31 | Not yet recruiting | ||
| Metformin Versus Metfotmin Plus Low-dose Spironolactone in the Treatment of Overweight/Obese Patients With Polycystic Ovary Syndrome: a Randomized Study[NCT01526616] | 56 participants (Actual) | Interventional | 2010-05-31 | Completed | |||
| 17-hydroxysteroid Dehydrogenase Type 5 Gene Polymorphism (71A/G HSD17B5 SNP) and Effects of Oral Contraceptive Pill on Hirsutism, Androgens and Metabolic Profile in Non-obese PCOS Women: a Pilot Study[NCT01372293] | 49 participants (Actual) | Interventional | 2005-01-31 | Completed | |||
| Effects of Inositol Alone or Associated With Alpha-lipoic Acid in Polycystic Ovary Syndrome Treatment[NCT04881851] | 90 participants (Anticipated) | Interventional | 2015-05-07 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 reviews available for spironolactone and Hyperandrogenism
| Article | Year |
|---|---|
Polycystic ovarian syndrome: Correlation between hyperandrogenism, insulin resistance and obesity.
Topics: Androgens; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; Insulin Resistance; Metformin; Obe | 2020 |
Female Pattern Hair Loss and Androgen Excess: A Report From the Multidisciplinary Androgen Excess and PCOS Committee.
Topics: 5-alpha Reductase Inhibitors; Alopecia; Androgen Antagonists; Female; Humans; Hyperandrogenism; Low- | 2019 |
Hirsutism in Women.
Topics: Adrenal Hyperplasia, Congenital; Androgen Antagonists; Antineoplastic Agents, Hormonal; Contraceptiv | 2019 |
Is hormonal treatment still an option in acne today?
Topics: Acne Vulgaris; Adrenal Cortex Hormones; Adult; Androgen Antagonists; Contraceptives, Oral, Hormonal; | 2015 |
Interventions for hirsutism excluding laser and photoepilation therapy alone: abridged Cochrane systematic review including GRADE assessments.
Topics: 5-alpha Reductase Inhibitors; Adolescent; Androgen Antagonists; Body Mass Index; Contraceptives, Ora | 2016 |
Oral Spironolactone for Acne Vulgaris in Adult Females: A Hybrid Systematic Review.
Topics: Acne Vulgaris; Administration, Oral; Adult; Androgens; Anti-Bacterial Agents; Contraceptives, Oral, | 2017 |
Anti-androgen treatments.
Topics: Androgen Antagonists; Cyproterone Acetate; Estrogens; Female; Finasteride; Flutamide; Gonadotropin-R | 2010 |
Best methods for identification and treatment of PCOS.
Topics: Androgens; Aromatase Inhibitors; Clomiphene; Contraceptives, Oral, Hormonal; Diagnosis, Differential | 2010 |
Update and future of hormonal therapy in acne.
Topics: Acne Vulgaris; Androgen Antagonists; Androgens; Contraceptives, Oral, Hormonal; Dehydroepiandrostero | 2003 |
8 trials available for spironolactone and Hyperandrogenism
| Article | Year |
|---|---|
Coadministration of metformin or spironolactone enhances efficacy of rosiglitazone in management of PCOS.
Topics: Adolescent; Adult; Drug Synergism; Drug Therapy, Combination; Female; Humans; Hyperandrogenism; Indi | 2020 |
In PCOS patients the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism than metformin alone.
Topics: Adult; Androstenedione; Dehydroepiandrosterone; Dose-Response Relationship, Drug; Female; Hirsutism; | 2014 |
Comparison of desogestrel/ethinyl estradiol plus spironolactone versus cyproterone acetate/ethinyl estradiol in the treatment of polycystic ovary syndrome: a randomized controlled trial.
Topics: Acne Vulgaris; Adult; Androgen Antagonists; Androgens; Androstenedione; Cholesterol; Contraceptives, | 2015 |
17-Hydroxysteroid dehydrogenase type 5 gene polymorphism (-71A/G HSD17B5 SNP) and treatment with oral contraceptive pills in PCOS women without metabolic comorbidities.
Topics: 3-Hydroxysteroid Dehydrogenases; Adolescent; Adult; Aldo-Keto Reductase Family 1 Member C3; Brazil; | 2012 |
Low dose spironolactone in the treatment of female hyperandrogenemia and hirsutism.
Topics: Adolescent; Adult; Female; Hirsutism; Humans; Hyperandrogenism; Infant, Newborn; Luteinizing Hormone | 1993 |
[Ovulation induction with adjuvant antiandrogen treatment in Stein-Leventhal syndrome].
Topics: Adult; Androgen Antagonists; Anovulation; Cyproterone Acetate; Dexamethasone; Female; Humans; Hypera | 1996 |
The addition of dexamethasone to antiandrogen therapy for hirsutism prolongs the duration of remission.
Topics: Adult; Androgen Antagonists; Cohort Studies; Dexamethasone; Drug Combinations; Female; Follow-Up Stu | 1998 |
The effect of combined oral contraception with or without spironolactone on bone mineral density of hyperandrogenic women.
Topics: Adult; Alkaline Phosphatase; Bone Density; Calcium; Contraceptives, Oral, Combined; Desogestrel; Dru | 2000 |
14 other studies available for spironolactone and Hyperandrogenism
| Article | Year |
|---|---|
Female Pelvic Conditions: Polycystic Ovary Syndrome.
Topics: Acne Vulgaris; Anovulation; Female; Finasteride; Gonadotropin-Releasing Hormone; Hirsutism; Humans; | 2022 |
[Spironolactone as a relay for cyproterone acetate in hyperandrogenic women].
Topics: Adult; Androgen Antagonists; Androstenedione; Cyproterone Acetate; Female; France; Humans; Hyperandr | 2020 |
Spironolactone in adolescent acne vulgaris.
Topics: Acne Vulgaris; Adolescent; Adult; Female; Humans; Hyperandrogenism; Mineralocorticoid Receptor Antag | 2021 |
Long-Term Response of Hirsutism and Other Hyperandrogenic Symptoms to Combination Therapy in Polycystic Ovary Syndrome.
Topics: Contraceptives, Oral; Cross-Sectional Studies; Drug Therapy, Combination; Female; Hirsutism; Humans; | 2018 |
Hirsutism - from diagnosis to use of antiandrogens.
Topics: Androgen Antagonists; Androstenes; Cyproterone Acetate; Female; Finasteride; Flutamide; Hirsutism; H | 2013 |
Symptomatic Cushing's syndrome and hyperandrogenemia in a steroid cell ovarian neoplasm: a case report.
Topics: Aged; Antineoplastic Agents, Hormonal; Cushing Syndrome; Disease Progression; Fatal Outcome; Female; | 2016 |
Aromatase gene polymorphism does not influence clinical phenotype and response to oral contraceptive pills in polycystic ovary syndrome women.
Topics: Adult; Androgens; Anovulation; Aromatase; Blood Pressure; Body Mass Index; Contraceptives, Oral; Eth | 2012 |
From HAIR-AN to eternity.
Topics: Acanthosis Nigricans; Child; Female; Hirsutism; Humans; Hyperandrogenism; Insulin Resistance; Polycy | 2002 |
Diagnosis and treatment of polycystic ovarian syndrome and insulin resistance.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Humans; Hyperandrogenism; Hyperlipidemia | 2005 |
The hyperandrogenic-insulin-resistant acanthosis nigricans syndrome: therapeutic response.
Topics: Acanthosis Nigricans; Adolescent; Contraceptives, Oral; Drug Therapy, Combination; Female; Humans; H | 1994 |
Antiandrogen treatment with spironolactone and linestrenol decreases bone mineral density in eumenorrhoeic women with androgen excess.
Topics: Adult; Bone Density; Female; Humans; Hyperandrogenism; Lynestrenol; Spironolactone | 1994 |
The insulin resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment: evidence that androgens impair insulin action in women.
Topics: Adult; Androgen Antagonists; Androgens; Buserelin; Female; Flutamide; Glucose Clamp Technique; Human | 1996 |
Successful treatment of hirsutism in HAIR-AN syndrome using flutamide, spironolactone, and birth control therapy.
Topics: Acanthosis Nigricans; Adolescent; Androgen Antagonists; Contraceptives, Oral, Combined; Contraceptiv | 1997 |
Comment on spironolactone, but not flutamide, administration prevents bone loss in hyperandrogenic women treated with gonadotropin-releasing hormone agonist.
Topics: Female; Flutamide; Gonadotropin-Releasing Hormone; Humans; Hyperandrogenism; Osteoporosis; Spironola | 1999 |